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Thehybridpathway forhemebiosynthesis in themalarial par-
asite proposes the involvement of parasite genome-coded
enzymes of the pathway localized in different compartments
such as apicoplast, mitochondria, and cytosol. However, knowl-
edge on the functionality and localization of many of these
enzymes is not available. In this study, we demonstrate that por-
phobilinogen deaminase encoded by the Plasmodium falcipa-
rum genome (PfPBGD) has several unique biochemical proper-
ties. Studies carried out with PfPBGD partially purified from
parasite membrane fraction, as well as recombinant PfPBGD
lacking N-terminal 64 amino acids expressed and purified from
Escherichia coli cells (PfPBGD), indicate that both the pro-
teins are catalytically active. Surprisingly, PfPBGD catalyzes the
conversion of porphobilinogen to uroporphyrinogen III (URO-
GEN III), indicating that it also possesses uroporphyrinogen III
synthase (UROS) activity, catalyzing the next step. This obviates
the necessity to have a separate gene forUROS that has not been
so far annotated in the parasite genome. Interestingly, PfP-
BGD gives rise to UROGEN III even after heat treatment,
although UROS from other sources is known to be heat-sensi-
tive. Based on the analysis of active site residues, a
PfPBGDL116K mutant enzyme was created and the specific
activity of this recombinant mutant enzyme is 5-fold higher than
PfPBGD.More interestingly,PfPBGDL116K catalyzes the for-
mation of uroporphyrinogen I (UROGEN I) in addition to URO-
GEN III, indicating that with increased PBGD activity the UROS
activity of PBGDmay perhaps become rate-limiting, thus leading
to non-enzymatic cyclization of preuroporphyrinogen to URO-
GEN I. PfPBGD is localized to the apicoplast and is catalytically
very inefficient compared with the host red cell enzyme.
Detailed studies of the metabolic pathways in the malarial
parasite hold promise for the identification of new antimalarial
drug targets (1, 2). Earlier studies in this laboratory had shown
that the malarial parasite synthesizes heme de novo, despite
acquiring heme from the host red cell hemoglobin in the
intraerythrocytic stage. It has been shown thatPlasmodium fal-
ciparum contains -aminolevulinate dehydratase (ALAD)2 of
dual origin: one species encoded by the parasite genome
(PfALAD) and another imported from the host red cell. Inhibi-
tion of ALAD activity in the parasite, the second enzyme of the
pathway with a specific inhibitor, succinylacetone, leads to
inhibition of heme synthesis and death of the parasite, indicat-
ing the potential of the pathway as a drug target (3, 4).
Heme biosynthesis from glycine and succinyl-CoA involves
eight different steps and the genes for all the enzymes of the
pathway, with the exception of uroporphyrinogen III synthase
(UROS, hemD) have been located on the parasite genome (5).
However, a hemD orthologue has been identified in Toxoplas-
ma gondii and is expected to be targeted to the apicoplast, a
chloroplast-like organelle in the parasite (6). Based mostly on
bioinformatics-based predictions, some experimental data and
hypothesis, a hybridmodel for heme biosynthesis has been pro-
posed. The model involves shuttling of intermediates of the
pathway betweenmitochondria, apicoplast, and cytoplasm and
the localization of the Pf enzymes in the different compart-
ments (6–9).However, experimental evidence for the function-
ality of the Pf enzymes in the parasite, and their actual site of
localization is available only in a few cases. Sato andWilson (10)
have shown that PfALAD is functional. Sato et al. (7) have also
shown that PfALA synthase (ALAS) and PfALAD are targeted
to the mitochondrion and apicoplast, respectively, based on
transfection studies in P. falciparum cultures involving GFP
fusion constructs. Studies in this laboratory have shown that
PfALAS is active and the native enzyme is localized to the par-
asitemitochondrion (11). PfALADandPf ferrochelatase (PfFC)
are also functional, and the native enzymes are localized to the
apicoplast (12, 13). However, it has been pointed out as unpub-
lished data (9) that in PfFC-GFP fusion gene-transfected para-
sites, the protein is targeted to the mitochondrion.
In the light of the dual origin of the enzymes of the heme-
biosynthetic pathway in the parasite (12–14), it is of importance
to establish the functionality of the Pf enzymes. A difficulty has
been to express adequate quantities of recombinant Pf
enzymes, perhaps due to the hydrophobicN-terminal targeting
sequence, AT-rich codon bias and recovery of recombinant
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proteins from the inclusion bodies. This laboratory has been
able to overcome these limitations by expressing the truncated
proteins without the hydrophobic targeting sequence, using
E. coliRosetta strain 2(DE3)pLysS that has seven tRNAs for rare
codons permitting universal translation and working out the
optimal conditions for expressing the recombinant proteins in
the cytosol. In the present study, the unique features of parasite
genome-coded porphobilinogen deaminase (PfPBGD) are
described. Surprisingly, the recombinant enzyme lacking the
N-terminal hydrophobic sequence (PfPBGD) is able to cata-
lyze the formation of UROGEN III, even after heat treatment,
rather than UROGEN I that is derived from pre-uroporphy-
rinogen in the absence of UROS, thus obviating the necessity
for a separate PfUROS. All the properties of the recombinant
enzyme including formation of UROGEN III, are also shown by
the native enzyme in the parasite. Sato et al. (7) have shown that
the N-terminal sequence of PfPBGD directs the reporter GFP
to the apicoplast in fusion gene-transfected parasites. The pres-
ent study reveals that the native PfPBGD is indeed localized to
the apicoplast. The enzyme is catalytically very inefficient,
when compared with the host red cell enzyme.
EXPERIMENTAL PROCEDURES
Parasite Maintenance and Isolation—P. falciparum culture
was maintained on human O red cells at 5% hematocrit in
RPMI 1640 with glutamine (Invitrogen) supplemented with
10% O human serum by the candle jar method (15). Cultures
were synchronized by sorbitol treatment (16), and the parasites
usually at the trophozoite stage were isolated by treatment with
equal volumes of 0.15% (w/v) saponin (17). The released para-
sites were pelleted down and washed four times with ice-cold
phosphate-buffered saline. The final wash was free of detecta-
ble hemoglobin.
Cloning, Expression, and Purification of PfPBGD cDNA—
The full-length PfPBGD could not be expressed in E. coli
Rosetta2(DE3)pLysS strain, but it was possible to express PfP-
BGD lacking 64N-terminal amino acids (PfPBGD).Again, the
protein expressed using pRSETA plasmid (Invitrogen) did not
bind to the Ni2-NTA column under non-denaturing condi-
tions, but the species expressed with C-terminal histidine tag
using pET-20b() plasmid (Invitrogen) bound to Ni2-NTA
column and could be purified. The 1.1-kb cDNA (Fig. 1A)
obtained using the primers, 5-GACCGGATCCGGGAACTC-
GTGATTCTCCG-3 and 5-ACCCTCGAGTTATTTATTA-
TTTAAAAGGTGCAATTCAGCCT-3, based on the nucleo-
tide sequence of putative PfPBGD gene sequence (PFL0480W)
described in PlasmoDB data base, was sequenced (ABI prism,
310 Genetic Analyzer) to confirm in-frame alignment of the
cloned cDNAwith the vector-encodedHis tag as well as for the
absence of PCR-based mutations.
Recombinant plasmids were transformed into E. coli
Rosetta2(DE3)pLysS strain (Novagen), and cells were grown to
an A600 of 1.0 at 30 °C in a rotary shaker. The cells were then
grown at 18 °C for 30 min, and protein expression was induced
with 1 mM 1-thio--D-galactopyranoside for 13 h at 18 °C. The
recombinant protein was recovered in both soluble (20–30%)
and membrane (70–80%) fractions. The soluble enzyme with
C-terminal histidine tag was purified by Ni2-NTA chroma-
tography under non-denaturing conditions. Briefly, E. coli cells
were lysed in 50mMTris buffer, pH 7.5, containing 50mMKCl,
10% glycerol, and 2 mM -mercaptoethanol by sonication. The
lysate was centrifuged at 50,000 g for 1 h, and the supernatant
was applied to a column packed with Ni2-NTA resin in the
presence of 15 mM imidazole. The column was then washed
sequentially with the lysis buffer containing 30, 50, and 75 mM
imidazole and finally thePfPBGDprotein was eluted from the
column with lysis buffer containing 300 mM imidazole and 1%
Triton X-100 (Fig. 1B). Following dialysis against lysis buffer,
the purified protein was stored at 4 °C up to one month. Host
PBGD was partially purified from human erythrocytes using
DEAE-cellulose and Q Sepharose as described (18, 19).
Generation of PfPBGDL116K Mutant—Site-directed
mutagenesis was carried out as described (20). The following
primer pair carrying the required mutations was used for
PCR amplification of pET-20b() plasmid containing
PfPBGD cDNA to generate the plasmid containing
PfPBGDL116K cDNA: 5-GT AAG AGT GTT GGA AAA
TAT GGC GGG AAAGG-3 and 5-CC TTT CCC GCC ATA
TTT TCC AAC ACT CTT AC-3. The mutant codons are
underlined. The PCR product obtained with Phusion High
Fidelity Polymerase was treated with DpnI to digest the meth-
ylated parental DNA strand, transformed into E. coli DH5
strain and ampicillin-resistant colonies were isolated. The plas-
mid containing PfPBGDL116K cDNA was isolated, and the
mutation was confirmed by DNA sequencing. Expression and
purification of PfPBGDL116K mutant protein from E. coli
Rosetta2(DE3)pLysS was carried out essentially as described
above.
EnzymeAssay—PfPBGDwas assayed essentially as described
by Jordan et. al (21) with 4 mM porphobilinogen (Sigma) in a
final volume of 50 l of 50 mM Tris, pH 7.5 containing 40 mM
KCl, 0.8% Triton, 8% glycerol, and 2 mM -mercaptoethanol.
Incubationwas carried out at 37 °C andhigher temperatures for
different periods of time. The reactionwas stopped by the addi-
tion of 30 l of 5 N HCl and porphyrinogens were oxidized to
porphyrins by exposure to light for 20min. The absorbancewas
measured at 405 nm against buffer blank (EmM  548 M1
cm1). An enzyme-omitted control was included in all the
assays. Host PBGD assay was carried out at pH 8.2 with 2 mM
porphobilinogen under the same conditions.
HPLC Analysis for Product Characterization—HPLC analy-
sis was carried out essentially as described by Lim et al. (22)
with Waters HPLC system (model 515, with dual absorbance
detector). Briefly, 25 l of the assay mixture was loaded onto a
C18 Sun Fire column (5 m, 4.6  250 mm). The solvent sys-
tem consisted of acetonitrile and 1M ammoniumacetate buffer,
pH 5.16. A 15-min linear gradient elution with 13% (v/v) aceto-
nitrile to 30% acetonitrile in ammoniumacetate buffer followed
by an isocratic elution at 30% acetonitrile for further 15minwas
used. Standard uroporphyrin I (URO I) and III (URO III) (Fron-
tier Scientific) were used to spike the reaction products to
enable characterization of the isomer (Supplemental Fig. S1A).
Identification of Dipyrromethane Cofactor—PurifiedPfPBGD
was treated with modified Ehrlich reagent (1 g of p-dimeth-
ylamino benzaldehyde in 8ml of 70% perchloric acid 42ml of
glacial acetic acid), and the spectrum was recorded at different
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intervals. The presence of dipyrromethane in the enzyme is
indicated by the formation of a purple color with an absorption
maximumaround 555 nmwithin 5min, with the color fading to
an orange-yellow color in about 20 min, with a new absorption
maximum around 495 nm (23).
Preparation of ParasiteMembrane Fraction—PBGD enzyme
activity was also assayed in parasite membrane (total organel-
lar) fraction prepared as described by Sharma et al. (24). For this
purpose, parasites were resuspended in 20 mM Tris (pH 7.5)
containing 250 mM sucrose and sonicated for 1 min at 30%
amplitude with alternative cooling. This lysate was centrifuged
at 150,000  g for 30 min, and the supernatant (cytosol) was
removed. The pellet was solubilized in a buffer containing 50
mM Tris, pH 7.5, 50 mM KCl, 1% Triton X-100, 2 mM -mer-
captoethanol, and 10% glycerol. The supernatant obtained after
centrifugation at 15,000 gwas used as solubilized membrane
fraction. Marker analysis of the parasite membrane and cytosol
fractions was carried out as described by Varadharajan et al.
(13). The solubilized membrane fraction was routinely heat-
treated at 80 °C for 20min before assaying for PfPBGD activity.
Localization of PfPBGD—To study the localization of PfPBGD
inP. falciparum themethod described by Tonkin et al. (25) was
followed. Polyclonal antibodies were raised against PfPBGD
in rabbit and IgG was purified using protein A Sepharose chro-
matography. The parasite-infected red blood cell pellet was
washed thrice with phosphate-buffered saline (PBS) and then
fixed with 4% paraformaldehyde (w/v) and 0.0075% glutaral-
dehyde (v/v) for 30 min. After washing with PBS, the fixed
cells were permeabilized with 1% Triton X-100 and treated
with 0.1 mg/ml (PBS) sodium borohydride for 10 min. Block-
ing was carried out with 3% bovine serum albumin. Rabbit
anti-PfPBGD IgG and mouse anti-PfALAD IgG or mouse
anti-PfALAS IgG were used at 1:200 dilution and incubated
for 2 h. FITC-conjugated goat anti-rabbit IgG and TRITC-
conjugated goat anti-mouse IgG (Santa Cruz Biotechnology)
were then added and incubated for 1 h at 1:200 dilution. Cells
were then allowed to settle onto poly-L-lysine coated cover-
slips (Sigma) and mounted in 50% glycerol with 0.1 mg/ml of
1,4-diazabicyclo[2,2,2]octane (DABCO, Sigma). Fluores-
cence microscope (Leica Microsystems) was used and
images were acquired at 100 magnification using an oil
immersion objective and Leica FW 4000 image acquisition
software.
Other Procedures—Western blot analysis of PfPBGD and
the parasite membrane fraction was carried out with purified
IgG (1:1000 dilution) using standard procedures.
RESULTS
Purification of PfPBGD—The PfPBGD lacking the 64
N-terminal amino acids of PfPBGD was expressed using pET-
20b() plasmid and purified from E. coli lysate by Ni2-NTA
chromatography (see “Experimental Procedures”). The puri-
fied protein appeared as a doublet on SDS gel (Fig. 1B, lane 6),
and the faint upper 45-kDa band may be because of the pres-
ence of the uncleaved periplasmic localization signal. The dou-
blet (45/43 kDa) reacted with monoclonal anti-histidine tag
antibody as well as anti-PfPBGD IgG (Fig. 1, C and D). This
recombinant enzyme designated as PfPBGD, and the host
enzyme partially purified from red cells were used in all subse-
quent studies.
Properties of PfPBGD—Initial studies with recombinant
enzyme purified using Ni2-NTA column did not show any
activitywhen incubated at 37 °C for 1 h, unlike the host enzyme.
Because PBGDs are known to be heat stable (21, 26), assays were
carriedout athigher temperatureswhen theenzymeactivity could
bedetected.Theoptimumtemperature forPfPBGDwas around
65 °C (Fig. 2A). The enzyme lost very little activity even when
heated to 80 °C and then assayed at
37 °C (Fig. 2B). The enzyme gave a
typical spectrum for the presence of
dipyrromethane cofactor with Ehr-
lich reagent (Fig. 2C). In view of
these results, assays were carried
out for prolonged periods of time at
37 °C. The enzyme activity picked
up after a lag of about 2 h and was
linear up to 12 h (Fig. 3A). The host
enzyme did not show a lag and
reached saturation in about 4 h (Fig.
3D). In general, the specific activity
of the host enzyme was 25–30-fold
higher than that of the PfPBGD.
The pH optima of PfPBGD and
FIGURE 1. Cloning and expression of truncated P. falciparum porphobi-
linogen deaminase (PfPBGD). A, cloning of PfPBGD cDNA into E. coli
expression vector. Lane 1, 1.1-kb PfPBGD cDNA obtained by RT-PCR; lane 2,
BamHI-XhoI digest of recombinant pET-20b() plasmid carrying PfPBGD
cDNA. LaneM, 1-kb ladder (kb). B, purification ofPfPBGD from E. coli cells by
Ni2-NTA affinity chromatography. Lane 1, E. coli cell lysate; lane 2, flow-
through fraction from Ni2-NTA column, lanes 3–5, washes with lysis buffer
containing 30, 50, and 75mM imidazole. Lane 6, heat-treated 300mM imidaz-
ole eluate of Ni2-NTA column; Lane M, protein molecular weight markers
(kDa). C and D, Western blot analysis of purified PfPBGD using mouse anti-
His tag antibody and rabbit anti-PfPBGD IgG.
FIGURE 2. Characteristics of PfPBGD. The enzyme was assayed by measuring the absorbance of the por-
phyrin product formed at 405 nmas described under “Experimental Procedures.” Activity is expressed in terms
of the porphyrin product formed. A, enzyme was incubated at the temperatures indicated for 1 h. B, enzyme
was pretreated at the temperatures indicated for 20min and then incubated at 37 °C for 12 h.NHT, non-heated
control activity was taken as 100% (3.8 nmol/mg protein/h). C, dipyrromethane identification in the purified
enzymewithmodified Ehrlich reagent. Continuous line, spectrum takenwithin 5min (peak at 555 nm); dashed
line, spectrum taken after 20 min (peak at 495 nm).
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host PBGDswere found to be in the ranges 7.1–7.5 and 8.1–8.4,
respectively (Fig. 3, B and E). There was substantial difference
in the Km values for PfPBGD (1.3 mM) and host enzyme (47.4
M) (Fig. 3, C and F).
PfPBGD Catalyzes Formation of Uroporphyrinogen III
(UROGEN III)—PBGDs catalyze the formation of pre-uro-
porphyrinogen which spontaneously cyclizes to UROGEN I
in the absence of UROS, the latter enzyme being responsible
for the formation of UROGEN III due to ring D inversion
(27). The UROS gene has not as yet been identified on the par-
asite genome, and this enzyme activity is essential for the nor-
mal functioning of the heme-biosynthetic pathway. Surpris-
ingly,PfPBGDwas found to give rise toUROGEN III (URO III
after oxidation). While spiking with standard URO III
enhanced the peak height of the product, spiking with URO I
gave a separate peak (Fig. 4, A–C). The standard method of
PBGD purification involves heat inactivation of UROS, but
interestingly, PfPBGD gave UROGEN III even after heat
treatment (Fig. 4, D–F). This unique property of the enzyme
obviates the necessity to have a separate gene for UROS on the
FIGURE 3. Properties of PfPBGD and host red cell PBGD. The enzymes were assayed under conditions described in the text. The host human red cell
enzymewaspartially purifiedandproteinestimatedafter SDS-PAGE. The topandbottom rowsdepict dataobtainedwithPfPBGDandhost PBGD, respectively.
A and D, time course; B and E, pH optima; C and F, Lineweaver-Burk plots.
FIGURE 4. Product characterization ofPfPBGD reaction. The enzymewas incubated with the substrate for 12 h, and the porphyrin product was analyzed
onHPLC column as described under “Experimental Procedures.” The top and bottom rows refer to the product analysis without andwith heat treatment (80 °C
for 20 min) of the recombinant enzyme. A and D, HPLC profile of product; B and E, product spiked with URO III; C and F, product spiked with URO I.
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parasite genome. As expected, the host red cell enzyme after
heat treatment gave rise to UROGEN I (URO I after oxidation)
(Supplemental Fig. S1, B–D).
Properties of PfPBGD from the Parasite—To carry out the
enzyme assay for the parasite genome-coded PBGD in P. falci-
parum, the parasite pellet was fractionated into membrane and
cytosol fractions as described under “Experimental Procedures.”
Western blot analysis was carried out with anti-PfPBGD
IgG. The results presented in Fig. 5, A and B indicate that a
43-kDa protein was detected only in the membrane fraction
and not in the cytosol. The total membrane pellet was solubi-
lized as described under “Experimental Procedures,” andPBGD
enzyme assays were carried out after heat treatment. All the
properties listed for the recombinant enzyme were also seen
with the native enzyme in the parasite. The time course kinetics
obtained was similar to that obtained with PfPBGD (Fig. 5C).
The Km was found to be 1.15 mM (Fig. 5D). Importantly, heat-
treated membrane fraction gave UROGEN III as the end prod-
uct (Fig. 5, E–G). The pH and temperature optima were similar
to that of the recombinant enzyme (data not presented).
To rule out the outside possibility of the presence of an inde-
pendent heat-stable PfUROS in the parasite membrane extract
and contribution of inadequately inactivated E. coli proteins as
contaminants in the purified recombinant PfPBGD to UROS
activity, the following control experiments were carried out:
The parasite membrane extract was immunoprecipitated with
anti-PfPBGD IgG, and the supernatant was assayed for PBGD
andUROS activities and neither activity could be detected. The
supernatant was also added to partially purified host PBGD to
look for UROS activity. The E. coli Rosetta strain, transformed
with pET-20b() without PfPBGD-cDNA, was assayed for
UROS activity after heat denaturation of the extract, as such
and in the presence of host PBGD. In all these experiments only
URO I was detected as the product of the reaction, and there
was no evidence for the formation ofURO III. These results rule
out any extraneous contribution to the bifunctional character
of PfPBGD (data not presented). Attempts to carry out comple-
mentation studies with E. coli hemDmutant (28) were not suc-
cessful, because PfPBGD expression required the use of the
Rosetta strain, and no detectable expression could be seen in
the mutant strain used.
Studies withPfPBGDMutant—Aperusal of the amino acid
sequence of PfPBGD (Fig. 6) reveals that it shares most of the
essential amino acid residues established with PBGDs from dif-
ferent sources (29, 30). Thus, it shares all the 8 arginines, the
mutation of which leads to a decrease in activity. In particular,
the parasite enzyme manifests the conserved motif VGTSSL
followed by arginines 131 and 132 in E. coli. (It is IGTSSL fol-
lowed by arginines 216 and 217 in the parasite.) It also shares
other conserved residues such as Gln19(75), Phe62(123),
Asp84(145), Leu159(244), and the active site Cys242(359), the num-
bers outside and inside the parenthesis indicating the positions
in E. coli and parasite enzymes, respectively (31). In addition,
PfPBGD shares the lysine 59 at an equivalent position, but
instead of lysine 55 it has leucine 116. It has been shown that
modification of one of the two conserved lysine residues leads
to inactivation of PBGD in E. coli (32). Therefore, it was of
interest to examine the contribution of leucine 116 to the low
activity of the parasite enzyme by changing the leucine back to
lysine, as is seen in the E. coli enzyme.
FIGURE 5. Properties of native PBGD in the membrane fraction from P. falciparum. The membrane fraction was prepared from the parasite pellet,
solubilized, and heat treated as described under “Experimental Procedures” and used for the assays. A and B, Western blot analysis of the membrane and
cytosolic fractions fromP. falciparum.M,marker;MF,membrane fraction;CY, cytosol fraction.C, timecourse.D, Lineweaver-Burkplot. E, HPLCprofile ofproduct.
F, product spiked with URO III. G, product spiked with URO I.
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The results obtained with
PfPBGDL116K indicate that the
mutant enzyme has at least 5-fold
higher activity than PfPBGD (Fig.
7A).More interestingly, the product
profile now indicates a significant
amount of URO I along with URO
III (Fig. 7, B–D).
Localization of PfPBGD in P.
falciparum—Immunofluorescence
studies were carried out to identify
the localization of native PfPBGD
using anti-PfPBGD IgG. This lab-
oratory has shown earlier that
PfALAD is localized to the apico-
plast (12), and PfALAS is localized
to the mitochondrion (11). The
results presented in Fig. 8 indicate
that PfPBGD colocalizes with
PfALAD but not with PfALAS,
establishing that the native enzyme
is localized to the apicoplast in the
parasite.
DISCUSSION
In this study, the parasite
genome-coded PBGD lacking the
hydrophobic N-terminal 64 amino
FIGURE6.Aminoacid sequencealignmentbetweenPBGDs fromE. coliandP. falciparum. The alignment has beenperformedusing the “needle” program
(Needleman-Wunsch global Alignment algorithm) of the EMBOSS suite. Identity: 101/451 (22.4%), Similarity: 172/451 (38.1%), Gaps: 154/451 (34.1%). Score:
381.0. Crucial identical amino acid residues are highlighted and discussed in the text.
FIGURE 7. Properties of thePfPBGDL116Kmutant enzyme. The mutant enzyme was generated and purified as
describedunder“ExperimentalProcedures.”A,activityofwild-typeandmutantenzymeswerecomparedwithincreasing
substrateconcentration.B–D, HPLCprofilesof theproductas such (B) andafter spikingwithURO III (C) andURO I (D).
FIGURE 8. Localization of PfPBGD with PfALAD and PfALAS in P. falciparum by immunofluorescence. The
experimental details are given under “Experimental Procedures.” IE, infected erythrocyte; P, parasite;H, hemozoin.
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acids containing the presumptive signal and transit peptide
targeting sequences was cloned, and the truncated protein
(PfPBGD) was overexpressed in E. coli, purified and bio-
chemically characterized. The unique feature is the identifi-
cation of UROGEN III as the end product, when this recom-
binant enzyme as well as the native enzyme present in
parasite membrane fractions were assayed for porphobilino-
gen deaminase enzyme activity. Although, Ralph et al. (6)
and Wilson (8) have alluded to the possible presence of a
candidate hemD gene (UROS) in P. falciparum, so far there
has been no report on the expression of this gene or charac-
terization of a separate UROS enzyme in the parasite. The
present study indicates that PfPBGD also has UROS activity
leading to the formation of UROGEN III. While information
on an independent UROS gene and purification of the
enzyme is available from different sources such as E. coli
(33), yeast (34), and the human (35) including its crystal
structure (36), there have been no reports on the enzyme or
gene from algal and plant sources (37). Interestingly, it has
been reported that in Leptospira interrogans hemC codes for
a bifunctional PBGD/UROS enzyme (38). Further studies are
needed to examine whether PfPBGD has segmental homol-
ogies to both hemC/hemD genes, or the entire protein is
required for the manifestation of both the activities as is the
case in Leptospira. It is also interesting to note that PfPBGD
manifests both the activities after heat treatment. It is known
that in general while PBGD is heat stable, UROS is heat-
sensitive, and heat treatment is included as a step in the
purification of PBGD (21, 26).
Another important feature of PfPBGD is its very low cata-
lytic efficiency when compared with the host enzyme, as
assessed using the recombinant enzyme. There is almost a
100-fold difference between the catalytic efficiencies of host
PBGD andPfPBGD, the kcat/Km (M1 s1) values being 5.43
and 0.0585, respectively. Although, PfPBGD has all the con-
served arginines and other amino acid residues considered
essential for the enzyme activity (29–31), there could be
other contributory regions, because the parasite enzyme has
only around 40% homology with the host red cell enzyme.
Studies with PfPBGDL116Kmutant enzyme indicate that a
change from the native leucine to lysine present in other
PBGDs leads to an increase in specific activity by 5-fold.
More interestingly, a significant amount of UROGEN I is
now seen along with UROGEN III as the product. This would
indicate that with increased PBGD activity, the UROS activ-
ity of PfPBGD, perhaps, becomes rate-limiting and allows
the non-enzymatic cyclization of pre-uroporphyrinogen
into UROGEN I.
Sato et al. (7) have earlier shown that the N-terminal 65
amino acid residues of PfPBGD fused with GFP is targeted to
the apicoplast, when the fusion gene is transfected into the par-
asite. The present studies with anti-PfPBGD antibodies reveal
that the native enzyme is indeed localized to the apicoplast.
Preliminary studies (unpublished) reveal that the parasite
cytosol contains imported host red cell PBGD. Earlier studies in
this laboratory have demonstrated the import of functional
host ALAD (12) and FC (13) into the parasite cytosol. It appears
that the parasite genome-coded heme-biosynthetic enzymes
aremuch less efficient than the imported host enzymes and the
two pathways in the parasite may be differently compartmen-
talized (39). These results call for a detailed assessment of the
contribution of imported hostVersus PfPBGD in parasite heme
biosynthesis.
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